Cover Image
市場調查報告書

液態生物檢體 (液態切片)的全球市場的分析與預測

Global Liquid Biopsy Market, Analysis and Forecast 2017-2025: Focus on Product Type, Therapeutic Application, End User, Market Share Analysis, Country Analysis and Competitive Landscape

出版商 BIS Research Inc. 商品編碼 587014
出版日期 內容資訊 英文 354 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
液態生物檢體 (液態切片)的全球市場的分析與預測 Global Liquid Biopsy Market, Analysis and Forecast 2017-2025: Focus on Product Type, Therapeutic Application, End User, Market Share Analysis, Country Analysis and Competitive Landscape
出版日期: 2017年12月01日 內容資訊: 英文 354 Pages
簡介

本報告提供全球液態生物檢體 (液態切片,按液體細胞診斷)的市場相關分析,市場概要和主要的促進、阻礙因素,市場競爭環境,市場規模趨勢預測 (今後9年份),各產品、生物標記、癌症的各類型、各終端用戶、各地區的詳細趨勢,主要企業簡介等調查。

摘要整理

第1章 分析範圍、手法

第2章 市場概要

第3章 市場動態

  • 液態生物檢體市場成長促進、阻礙因素
  • 市場的推動要素
  • 市場的阻礙要素
  • 市場機會

第4章 競爭分析

  • 市場主要動向與策略
  • 競爭環境
  • 市場佔有率分析
  • 市場向心力:波特的五力分析

第5章 全球液態生物檢體市場:各產品

  • 概要
  • 試劑組、消耗品
  • 檢查裝置
  • 檢驗服務

第6章 全球液態生物檢體市場:生物標記的各類型

  • 概要
  • 循環腫瘤細胞 (CTC)
  • 循環腫瘤DNA (ctDNA)
  • 細胞外小胞 (EV)
  • 其他的種類的生物標記

第7章 全球液態生物檢體市場:癌症的各類型

  • 癌症檢測中液態生物檢體的作用:概要
  • 肺癌症診斷中液態生物檢體的作用
  • 乳癌診斷中液態生物檢體的作用
  • 大腸癌症診斷中液態生物檢體的作用
  • 前列腺癌症診斷中液態生物檢體的作用
  • 肝臟癌症診斷中液態生物檢體的作用
  • 其他癌症診斷中液態生物檢體的作用

第8章 全球液態生物檢體市場:各終端用戶

  • 概要
  • 參考檢驗室
  • 醫院、開業醫生的檢驗室
  • 教育、研究機關
  • 其他終端用戶

第9章 全球液態生物檢體市場:各地區

  • 概要
  • 北美 (美國,加拿大)
  • 歐洲 (英國,德國,法國等)
  • 亞太地區 (中國,日本,印度等)
  • 其他的國家 (RoW)

第10章 企業簡介

  • Adaptive Biotechnologies
    • 概要
    • 企業概要
    • 財務分析
    • SWOT分析
  • ANGLE plc
  • Biocept, Inc.
  • Bio-Rad Laboratories, Inc.
  • CareDx, Inc.
  • Cynvenio Biosystems, Inc.
  • Epic Sciences, Inc.
  • F. Hoffmann-La Roche AG
  • Genomic Health, Inc.
  • GUARDANT HEALTH, INC
  • Illumina, Inc.
  • JOHNSON & JOHNSON
  • MDxHealth, Inc.
  • Menarini Silicon Biosystems, Inc.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • NeoGenomics Laboratories, Inc.
  • QIAGEN
  • RainDance Technologies, Inc.
  • Sysmex
  • Thermo Fisher Scientific
  • TROVAGENE, INC.
目錄
Product Code: BH038A

A biopsy is the most common, definitive medical procedure used for cancer diagnosis and treatment monitoring. Tissue biopsy, is widely adopted procedure to diagnose cancer. However, a major drawback for tissue based diagnosis approach is its dependency on invasive surgical procedures which in many instances preclude the regular treatment monitoring and sometimes the initial diagnosis too. The search for better minimal invasive diagnostic procedures to aid regular monitoring of the patient's response towards the treatment gave birth to liquid biopsy tests. In the recent years, the impressive research on cancer biomarkers' presence in biological fluids, such as blood, which can be collected through minimal invasive techniques has yielded promising results to develop better minimal invasive diagnostics procedures known as liquid biopsies.

Liquid biopsy is a minimal invasive medical procedure with the ability to detect the presence of molecular cancer biomarkers in the biological fluids. The derived test results help the doctors in deciding the further steps in the treatment of the patient suffering from cancer. The test principally involves the usage of samples of biological fluids, such as blood, urine, serum, and saliva, among others, and then the enrichment of the samples using different techniques, such as Next generation Sequencing (NGS), and Polymerase Chain Reaction (PCR), to detect the mutations known to cause cancer.

The liquid biopsy market is expected to grow at a near double digit annual growth rate. The abilities of liquid biopsy, such as minimal invasiveness, possibility of continuous monitoring of the patient's response towards treatment, and the monitoring of clonal mutations, combined with the growing prominence for precision medicine have fueled the growth of the liquid biopsy market.

The research study comprises in-depth analysis of the market trends and market size through different approaches. The entire market has been segmented and estimated in five different approaches, namely "by product & services", "by biomarker and technology", "by cancer type", "by end users", and "by geography".

In terms of "by products & services", the market has been segmented into kits & reagents, platforms & instruments, and services. In terms of "by biomarker and technology" the market has been segmented into circulating tumor cell (CTC), circulating tumor DNA (ctDNA), and extracellular vesicles (EV). In terms of "by cancer type" the market has been segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, and liver cancer. In terms of "by end users" the market has been tracked through hospital & laboratory, government & academic research centers. And in terms of "by geography" the market has been segmented into North America, Europe, Asia Pacific, and LAMEA.

Some of the key players who have been contributing significantly to the liquid biopsy market are Janssen Diagnostics, LLC; Biocept Inc., Bio-Rad Laboratories Inc., Guardant Health, Inc., Myriad Genetics, QIAGEN, RainDance Technologies, Roche AG, Trovagene Inc., Adaptive Biotechnologies, Natera, Inc., Cynvenio Biosystems, Inc., Epic Sciences, ANGLE plc, Illumina, Inc., Menarini Silicon Biosystems., MDxHealth, Sysmex Inostics GmbH, Genomic Health, and NeoGenomics Laboratories, Inc.

The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into the consideration before entering into the global liquid biopsy market.

The answers to the following key questions can be derived from this report:

  • What are the major market drivers, challenges, and opportunities in the global liquid biopsy market?
  • How did the liquid biopsy market evolve and what is its scope in the future?
  • What are the key developmental strategies which are being implemented by the key players to stand out in this market?
  • What is the total addressable market (TAM), segmental addressable market (SAM) and the potential market opportunity of the global liquid biopsy market?
  • What is the market share of the leading segments and sub-segments of the liquid biopsy market in 2016 and 2025?
  • How will each segment of the global liquid biopsy market grow during the forecast period and what will be their revenue generation at the end of 2025?
  • Who are the key players dominating the global liquid biopsy market and their respective share?
  • What are the influencing factors that may affect the market share of the key players?
  • How will the industry evolve during the forecast period 2016-2025?
  • Which product type is dominating the market?
  • What are the dominating products offered by different companies for each product type, available in the market?
  • How the market is distributed on the basis of application?
  • Which cancer type is the leading contributor to the global liquid biopsy market revenue?
  • Which geographical location will contribute to the highest sales of the liquid biopsy products?

This research report aims at answering various aspects of the global liquid biopsy market with the help of key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The study considers the growth-share matrix model for a comprehensive study of the global liquid biopsy market and assesses the factors governing the same.

Executive Summary

A biopsy is the most common, definitive medical procedure used for cancer diagnosis and treatment monitoring. Tissue biopsy is the most widely adopted procedure to diagnose cancer. However, a major drawback of the tissue based diagnosis approach is its dependency on invasive surgical procedures which in many instances preclude the regular treatment monitoring and sometimes the initial diagnosis too.

The search for better minimally invasive diagnostic procedures to aid the regular monitoring of the patient's response towards the treatment, have paved pathway for the most awaited change in diagnostic procedures. In the recent years, the impressive research on cancer biomarkers' presence in biological fluids, such as blood, which can be collected through minimally invasive techniques has opened up new hopes to develop promising minimally invasive diagnostic procedures. These procedures developed based on the detection of biomarkers in biological fluids which were later named as Liquid biopsy.

Liquid biopsy is a non-invasive medical procedure which has the ability to detect the presence of molecular cancer biomarkers in biological fluids. The derived test results help the doctors in deciding the further steps in the treatment of the cancer patients.

The purpose of the study is to gain a holistic view of the liquid biopsy market in terms of various factors influencing it, such as recent trends, technological advancements, and regulatory aspects of the market. The scope of this report is centered upon conducting a detailed study of the solutions allied with the liquid biopsy market. The global liquid biopsy market has been segmented into five different parts, namely by product, by type of biomarker and technology, by application, by end user, and by geography. These segments have been further segmented into many sub segments to ease the market estimation and to gain a holistic view of the market.

The global liquid biopsy market is anticipated to grow over $4,434 million by 2025. With the growing prominence for non-invasive diagnostic procedures, the global liquid biopsy market is expected to register an impressive double digit growth rate in the forecast period 2016-2025. The global liquid biopsy market, by product, is being dominated by Kits & Consumables, the sub segment was reported to contribute approximately 63% to the global liquid biopsy market value in 2016. The sub segment is expected to maintain its dominating share and is estimated to contribute approximately 61% to the global liquid biopsy market value in 2025.

On the other hand, the global liquid biopsy market, by type of biomarker, is being dominated by Circulating Tumor Cells (CTCs), the sub segment was reported to contribute 56% to the global liquid biopsy market value in 2016. The sub segment is expected to maintain its dominating market share and is estimated to contribute approximately 45% to the global liquid biopsy market value in 2025.

Additionally, the global liquid biopsy market, by application, is being dominated by Oncology Application. The sub segment was estimated to contribute 97% to the global liquid biopsy market value in 2016. The sub segment is expected to maintain its leading share and is estimated to contribute approximately 92% to the global liquid biopsy market value in 2025. The North America liquid biopsy market held the largest market share in 2016. The Asia Pacific liquid biopsy market is expected to register the highest CAGR of 26.3% in the forecast period 2016-2025.

The key players of the market include Adaptive Biotechnologies, ANGLE plc, Biocept Inc., Bio-Rad Laboratories Inc., Cynvenio Biosystems, Inc., Epic Sciences, F. Hoffmann-La Roche AG, Genomic Health, Guardant Health, Inc., Illumina, Inc., Janssen Diagnostics, LLC, MDxHealth, Menarini Silicon Biosystems., Myriad Genetics, Natera, Inc., NeoGenomics Laboratories, Inc., QIAGEN, RainDance Technologies, Inc., Sysmex Inostics GmbH, Thermo Fisher Scientific, and Trovagene Inc.

Currently, a significant work is being carried out to develop medical procedure based on liquid biopsy, for diagnosis of several diseases other than cancer. Through the detection of different biomarkers, the diagnosis of cardiovascular diseases, infections, immunological and genetic disorders is certainly possible and opens new hopes for the patients. The development of test kits to diagnose the above mentioned diseases appears to be a great opportunity to serve the market, for both the new and the existing players.

Table of Contents

Executive Summary

1 Report Scope & Methodology

  • 1.1 Scope of the Report
  • 1.2 Market segmentation
  • 1.3 Research Methodology
    • 1.3.1 Data Triangulation
    • 1.3.2 Key Data Points From Primary Sources
    • 1.3.3 Key Data Points From Secondary Sources
    • 1.3.4 Secondary Data Sources
    • 1.3.5 Top-Down Approach (Segmental Analysis)
    • 1.3.6 Bottom-Up Approach (Segmental Analysis)
  • 1.4 Assumptions and Limitations
  • 1.5 Data and Prediction Modelling

2 Market Overview

  • 2.1 Introduction
  • 2.2 Overview of Liquid Biopsy Techniques and Applications
  • 2.3 Historical trends
  • 2.4 Comparative Analysis of Tissue Biopsy and Liquid Biopsy

3 Market Dynamics

  • 3.1 Promoting and Inhibiting Factors of Liquid Biopsy Market Growth
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities

4 Competitive Insights

  • 4.1 Share of Key Development and Strategies
  • 4.2 Competitive Landscape
  • 4.3 Market Share Analysis
  • 4.4 Industry Attractiveness
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Buyers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 Global Liquid Biopsy Market, by Product

  • 5.1 Overview
  • 5.2 Kits and Consumables
  • 5.3 Instruments
  • 5.4 Services

6 Global Liquid Biopsy Market, by Type of Biomarker

  • 6.1 Overview
  • 6.2 Circulating Tumor Cell (CTC)
  • 6.3 Circulating Tumor DNA (ctDNA)
  • 6.4 Extracellular Vesicles (EVs)
  • 6.5 Other Types of Biomarkers

7 Global Liquid Biopsy Market, by Cancer Type

  • 7.1 Liquid Biopsy's Role in Cancer Detection: An Overview
  • 7.2 Liquid Biopsy: Role in Lung Cancer Diagnosis
  • 7.3 Liquid Biopsy: Role in Breast Cancer Diagnosis
  • 7.4 Liquid Biopsy: Role in Colorectal Cancer Diagnosis
  • 7.5 Liquid Biopsy: Role in Prostate Cancer Diagnosis
  • 7.6 Liquid Biopsy: Role in Liver Cancer Diagnosis
  • 7.7 Liquid Biopsy: Role in Other Cancer Diagnosis

8 Global Liquid Biopsy Market, by End User

  • 8.1 Overview
  • 8.2 Reference Laboratories
  • 8.3 Hospitals and Physician Laboratories
  • 8.4 Academic and Research Centers
  • 8.5 Other End Users

9 Global Liquid Biopsy Market, by Geography

  • 9.1 Overview
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 U.K.
    • 9.3.2 Germany
    • 9.3.3 France
    • 9.3.4 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Rest of the Asia Pacific
  • 9.5 Rest of the World

10 Company Profile

  • 10.1 Adaptive Biotechnologies
    • 10.1.1 Overview
    • 10.1.2 Adaptive Biotechnologies: Corporate Summary
    • 10.1.3 Adaptive Biotechnologies: SWOT Analysis
  • 10.2 ANGLE plc
    • 10.2.1 Overview
    • 10.2.2 Financials
    • 10.2.2.1 Financial Summary
    • 10.2.3 ANGLE plc: SWOT Analysis
  • 10.3 Biocept, Inc.
    • 10.3.1 Overview
    • 10.3.2 Financials
    • 10.3.2.1 Financial Summary
    • 10.3.3 Biocept, Inc.: SWOT Analysis
  • 10.4 Bio-Rad Laboratories, Inc.
    • 10.4.1 Overview
    • 10.4.2 Bio-Rad Laboratories, Inc.: Product Portfolio
    • 10.4.3 Financials
    • 10.4.3.1 Financial Summary
    • 10.4.4 Bio-Rad Laboratories, Inc.: SWOT Analysis
  • 10.5 CareDx, Inc.
    • 10.5.1 Overview
    • 10.5.2 Financials
    • 10.5.2.1 Financial Summary
    • 10.5.3 CareDx, Inc.: SWOT Analysis
  • 10.6 Cynvenio Biosystems, Inc.
    • 10.6.1 Overview
    • 10.6.2 Cynvenio Biosystems, Inc.: Product Portfolio
    • 10.6.3 Corporate Summary
    • 10.6.4 Cynvenio Biosystems, Inc.: SWOT Analysis
  • 10.7 Epic Sciences, Inc.
    • 10.7.1 Overview
    • 10.7.2 Epic Sciences, Inc.: Corporate Summary
    • 10.7.3 Epic Sciences, Inc.: SWOT Analysis
  • 10.8 F. Hoffmann-La Roche AG
    • 10.8.1 Overview
    • 10.8.2 F. Hoffmann-La Roche AG: Product Portfolio
    • 10.8.3 Financials
    • 10.8.3.1 Financial Summary
    • 10.8.4 F. Hoffmann-La Roche AG: SWOT Analysis
  • 10.9 Genomic Health, Inc.
    • 10.9.1 Overview
    • 10.9.2 Genomic Health, Inc.: Product Portfolio
    • 10.9.3 Financials
    • 10.9.3.1 Financial Summary
    • 10.9.4 Genomic Health, Inc.: SWOT Analysis
  • 10.10 GUARDANT HEALTH, INC
    • 10.10.1 Overview
    • 10.10.2 GUARDANT HEALTH, INC: Corporate Summary
    • 10.10.3 GUARDANT HEALTH, INC: SWOT Analysis
  • 10.11 Illumina, Inc.
    • 10.11.1 Overview
    • 10.11.2 Illumina, Inc.: Product Portfolio
    • 10.11.3 Financials
    • 10.11.3.1 Financial Summary
    • 10.11.4 Illumina, Inc.: SWOT Analysis
  • 10.12 JOHNSON & JOHNSON
    • 10.12.1 Overview
    • 10.12.2 JOHNSON & JOHNSON: Product Portfolio
    • 10.12.3 Financials
    • 10.12.3.1 Financial Summary
    • 10.12.4 JOHNSON & JOHNSON: SWOT Analysis
  • 10.13 MDxHealth, Inc.
    • 10.13.1 Overview
    • 10.13.2 Financials
    • 10.13.2.1 Financial Summary
    • 10.13.3 MDxHealth, Inc.: SWOT Analysis
  • 10.14 Menarini Silicon Biosystems, Inc.
    • 10.14.1 Overview
    • 10.14.2 Menarini Silicon Biosystems, Inc.: Product Portfolio
    • 10.14.3 Corporate Summary
    • 10.14.4 Menarini Silicon Biosystems, Inc.: SWOT Analysis
  • 10.15 Myriad Genetics, Inc.
    • 10.15.1 Overview
    • 10.15.2 Myriad Genetics, Inc.: Product Portfolio
    • 10.15.3 Financials
    • 10.15.3.1 Financial Summary
    • 10.15.4 Myriad Genetics, Inc.: SWOT Analysis
  • 10.16 Natera, Inc.
    • 10.16.1 Overview
    • 10.16.2 Natera, Inc.: Product Portfolio
    • 10.16.3 Financials
    • 10.16.3.1 Financial Summary
    • 10.16.4 Natera, Inc.: SWOT Analysis
  • 10.17 NeoGenomics Laboratories, Inc.
    • 10.17.1 Overview
    • 10.17.2 NeoGenomics Laboratories, Inc.: Product Portfolio
    • 10.17.3 Financials
    • 10.17.3.1 Financial Summary
    • 10.17.4 NeoGenomics Laboratories, Inc.: SWOT Analysis
  • 10.18 QIAGEN
    • 10.18.1 Overview
    • 10.18.2 QIAGEN: Product Portfolio
    • 10.18.3 Financials
    • 10.18.3.1 Financial Summary
    • 10.18.4 QIAGEN: SWOT Analysis
  • 10.19 RainDance Technologies, Inc.
    • 10.19.1 Overview
    • 10.19.2 RainDance Technologies, Inc.: Product Portfolio
    • 10.19.3 Financials
    • 10.19.3.1 Financial Summary
    • 10.19.4 RainDance Technologies, Inc.: SWOT Analysis
  • 10.20 Sysmex Corporation
    • 10.20.1 Overview
    • 10.20.2 Sysmex Corporation: Product Portfolio
    • 10.20.3 Financials
    • 10.20.3.1 Financial Summary
    • 10.20.4 Sysmex Corporation: SWOT Analysis
  • 10.21 Thermo Fisher Scientific
    • 10.21.1 Overview
    • 10.21.2 Thermo Fisher Scientific: Product Portfolio
    • 10.21.3 Financials
    • 10.21.3.1 Financial Summary
    • 10.21.4 Thermo Fisher Scientific: SWOT Analysis
  • 10.22 TROVAGENE, INC.
    • 10.22.1 Overview
    • 10.22.2 TROVAGENE, INC.: Product Portfolio
    • 10.22.3 Financials
    • 10.22.3.1 Financial Summary
    • 10.22.4 TROVAGENE, INC.: SWOT Analysis

List of Tables

  • 1 Cancer Incidence by Region, 2012 (Thousands)
  • 2 Tissue Biopsy vs. Liquid Biopsy
  • 3 Joint Ventures, Partnerships, Agreements and Collaborations
  • 4 Product Launch
  • 5 Mergers and Acquisitions
  • 6 Regulatory Approval
  • 7 Expansions and Others
  • 8 List of Available Kits in the Market
  • 9 List of Available Instruments and Platforms in the Market
  • 10 List of Tests Available in the Market
  • 11 Lung Cancer Incidence in Top Countries (2014-2025)
  • 12 Breast Cancer Incidence in Top Countries (2014-2025)
  • 13 Colorectal Cancer Incidence in Top Countries (2014-2025)
  • 14 Prostate Cancer Incidence in Top Countries (2014-2025)
  • 15 Liver Cancer Incidence in Top Countries (2014-2025)
  • 16 Incidence Rate of Different Cancer Types, U.S. (2014-2025)
  • 17 Incidence Rate of Different Cancer Types, Canada (2014-2025)
  • 18 Incidence Rate of Different Cancer Types, U.K. (2014-2025)
  • 19 Incidence Rate of Different Cancer Types, Germany (2014-2025)
  • 20 Incidence Rate of Different Cancer Types, France (2014-2025)
  • 21 Incidence Rate of Different Cancer Types, Italy (2014-2025)
  • 22 Incidence Rate of Different Cancer Types, China (2014-2025)
  • 23 Incidence Rate of Different Cancer Types, Japan (2014-2025)
  • 24 Incidence Rate of Different Cancer Types, India (2014-2025)
  • 25 Incidence Rate of Different Cancer Types, Australia (2014-2025)
  • 26 Incidence Rate of Different Cancer Types, South Korea (2014-2025)
  • 27 Incidence Rate of Different Cancer Types, Mexico (2014-2025)
  • 28 Incidence Rate of Different Cancer Types, Turkey (2014-2025)
  • 29 Incidence Rate of Different Cancer Types, Saudi Arabia (2014-2025)
  • 30 Adaptive Biotechnologies: Overview
  • 31 ANGLE plc: Overview
  • 32 Biocept, Inc.: Overview
  • 33 Bio-Rad Laboratories, Inc.: Overview
  • 34 CareDx, Inc.: Overview
  • 35 Cynvenio Biosystems, Inc.: Overview
  • 36 Epic Sciences, Inc.: Overview
  • 37 F. Hoffmann-La Roche AG: Overview
  • 38 Genomic Health, Inc.: Overview
  • 39 GUARDANT HEALTH, INC: Overview
  • 40 Illumina, Inc.: Overview
  • 41 JOHNSON & JOHNSON: Overview
  • 42 MDxHealth, Inc.: Overview
  • 43 Menarini Silicon Biosystems, Inc.: Overview
  • 44 Myriad Genetics, Inc.: Overview
  • 45 Natera, Inc.: Overview
  • 46 NeoGenomics Laboratories, Inc.: Overview
  • 47 QIAGEN: Overview
  • 48 RainDance Technologies, Inc.: Overview
  • 49 Sysmex Corporation: Overview
  • 50 Thermo Fisher Scientific: Overview
  • 51 TROVAGENE, INC.: Overview

List of Figures

  • 1 Global Liquid Biopsy Market Revenue (2016-2025)
  • 2 Global Liquid Biopsy Market Share, by Products and Services (2016)
  • 3 Global Liquid Biopsy Market Share, by Products and Services (2025)
  • 4 Global Liquid Biopsy Market Share, by Type of Biomarker (2016)
  • 5 Global Liquid Biopsy Market Share, by Type of Biomarker (2025)
  • 6 Global Liquid Biopsy Market Share, by Application (2016)
  • 7 Global Liquid Biopsy Market Share, by Application (2025)
  • 8 Global Liquid Biopsy Market Share, by End-User (2016)
  • 9 Global Liquid Biopsy Market Share, by End-User (2025)
  • 10 Liquid Biopsy Market Size, by Region
  • 11 Liquid Biopsy Market Segmentation
  • 12 Research Methodology
  • 13 Evolution of Liquid Biopsy with Progress in Molecular Technologies and Biomarker Discovery
  • 14 Comparative Analysis of Tissue Biopsy and Liquid Biopsy
  • 15 Share of Key Development and Strategies
  • 16 Market Share Analysis, by Companies (2015)
  • 17 Market Share Analysis, by Companies (2016)
  • 18 Porter's Five Forces Analysis
  • 19 Product Type Segmentation
  • 20 Global Liquid Biopsy Market, by Product, 2016-2025 ($Million)
  • 21 Global Liquid Biopsy Market Share, by Product, 2016-2025
  • 22 Global Liquid Biopsy Kits & Consumables Market, 2016-2025
  • 23 Global Liquid Biopsy Instruments Market, 2016-2025 ($Million)
  • 24 Global Liquid Biopsy Services Market, 2016-2025 ($Million)
  • 25 Different Biomarkers
  • 26 Global Liquid Biopsy Market, by Biomarker Type, 2016-2025 ($Million)
  • 27 Global liquid Biopsy Market, by Circulating Tumor Cells (CTCs), 2016-2025 ($Million)
  • 28 List of Few CTC Based Kits and Instrument
  • 29 Global liquid Biopsy Market, by Circulating Tumor DNA (ctDNA), 2016-2025 ($Million)
  • 30 List of Few ctDNA Based Kits and Instrument
  • 31 CTCs Vs ctDNA Analysis
  • 32 Global liquid Biopsy Market, by Extracellular Vesicles (EVs), 2016-2025 ($Million)
  • 33 Global liquid Biopsy Market, by Other Biomarkers (Cell Free DNA, etc.), 2016-2025 ($Million)
  • 34 Standard Biopsy Vs Liquid Biopsy
  • 35 Types of Lung Cancer
  • 36 Lung Cancer Incidence Rate Statistics
  • 37 List of Few Kits and Instruments for Lung Cancer Diagnosis
  • 38 Types of Breast cancer
  • 39 Breast Cancer Incidence Statistics
  • 40 List of Few Kits and Instruments for Breast Cancer Diagnosis
  • 41 Infected Colon and Rectum
  • 42 List of Few Kits and Instruments for Colorectal Cancer Diagnosis
  • 43 Colorectal Cancer Incidence Statistics
  • 44 Prostate Cancer Incidence Statistics
  • 45 List of Few Kits and Instruments for Prostate Cancer Diagnosis
  • 46 Types of Liver Cancer
  • 47 Liver Cancer Incidence Statistics
  • 48 Global Liquid Biopsy Market Share, by End Users, 2016-2025
  • 49 Global Liquid Biopsy Market, by End Users, 2016-2025 ($Million)
  • 50 Global Liquid Biopsy End User Market, Reference Laboratories, 2016-2025 ($Million)
  • 51 Global Liquid Biopsy End User Market, Hospitals and Physician Laboratories, 2016-2025 ($Million)
  • 52 Global Liquid Biopsy End User Market, Academic and Research Centers, 2016-2025 ($Million)
  • 53 Global Liquid Biopsy End User Market, Others, 2016-2025 ($Million)
  • 54 Global Liquid Biopsy Market, by Region
  • 55 Global Liquid Biopsy Market Revenue, by Region (2016-2025)
  • 56 Global Liquid Biopsy Market Share, by Region (2016)
  • 57 Global Liquid Biopsy Market Share, by Region (2025)
  • 58 North America Liquid Biopsy Market Revenue (2016-2025)
  • 59 North America Liquid Biopsy Market, by Products & Services (2016-2025)
  • 60 North America Liquid Biopsy Market, by Country (2016-2025)
  • 61 U.S. Liquid Biopsy Market Revenue (2016-2025)
  • 62 Canada Liquid Biopsy Market Revenue (2016-2025)
  • 63 Europe Liquid Biopsy Market Revenue (2016-2025)
  • 64 Europe Liquid Biopsy Market, by Products & Services (2016-2025)
  • 65 Europe Liquid Biopsy Market, by Country (2016-2025)
  • 66 U.K. Liquid Biopsy Market Revenue (2016-2025)
  • 67 Germany Liquid Biopsy Market Revenue (2016-2025)
  • 68 France Liquid Biopsy Market Revenue (2016-2025)
  • 69 Rest of Europe Liquid Biopsy Market Revenue (2016-2025)
  • 70 Asia Pacific Liquid Biopsy Market Revenue (2016-2025)
  • 71 Asia Pacific Liquid Biopsy Market, by Products & Services (2016-2025)
  • 72 Asia Pacific Liquid Biopsy Market, by Country (2016-2025)
  • 73 China Liquid Biopsy Market Revenue (2016-2025)
  • 74 Japan Liquid Biopsy Market Revenue (2016-2025)
  • 75 India Liquid Biopsy Market Revenue (2016-2025)
  • 76 Rest of Asia Pacific Liquid Biopsy Market Revenue (2016-2025)
  • 77 Rest of the World (RoW) Liquid Biopsy Market Revenue (2016-2025)
  • 78 Adaptive Biotechnologies: SWOT Analysis
  • 79 ANGLE plc: Overall Financials (2014-2016)
  • 80 ANGLE plc: Revenue by Region
  • 81 ANGLE plc: SWOT Analysis
  • 82 Biocept, Inc.: Overall Financials (2014-2016)
  • 83 Biocept, Inc.: SWOT Analysis
  • 84 Bio-Rad Laboratories, Inc.: Product Mapping
  • 85 Bio-Rad Laboratories, Inc.: Overall Financials (2014-2016)
  • 86 Bio-Rad Laboratories, Inc.: Net Revenue by Business Segment (2014-2016)
  • 87 Bio-Rad Laboratories, Inc.: Revenue by Region (2014-2016)
  • 88 Bio-Rad Laboratories, Inc.: SWOT Analysis
  • 89 CareDx: Overall Financials (2014-2016)
  • 90 CareDx, Inc.: SWOT Analysis
  • 91 Cynvenio Biosystems, Inc.: Product Mapping
  • 92 Cynvenio Biosystems, Inc.: SWOT Analysis
  • 93 Epic Sciences, Inc.: SWOT Analysis
  • 94 F. Hoffmann-La Roche AG: Product Mapping
  • 95 F. Hoffmann-La Roche AG: Overall Financials (2014-2016)
  • 96 F. Hoffmann-La Roche AG: Revenue By Geographical Area (2014-2016)
  • 97 F. Hoffmann-La Roche AG: Revenue by Division (2014-2016)
  • 98 F. Hoffmann-La Roche AG: Revenue By Diagnostics Sub-Division (2014-2016)
  • 99 F. Hoffmann-La Roche AG: SWOT Analysis
  • 100 Genomic Health, Inc.: Product Mapping
  • 101 Genomic Health, Inc.: Overall Financials (2014-2016)
  • 102 Genomic Health, Inc.: Net Revenue by Region (2014-2016)
  • 103 Genomic Health, Inc.: SWOT Analysis
  • 104 GUARDANT HEALTH, INC: SWOT Analysis
  • 105 Illumina, Inc: Product Mapping
  • 106 Illumina, Inc.: Overall Financials (2014-2016)
  • 107 Illumina, Inc.: Net Revenue by Business Segment (2014-2016)
  • 108 Illumina, Inc.: Revenue by Region (2014-2016)
  • 109 Illumina, Inc.: SWOT Analysis
  • 110 JOHNSON & JOHNSON: Product Mapping
  • 111 JOHNSON & JOHNSON: Overall Financials (2014-2016)
  • 112 JOHNSON & JOHNSON: Net Revenue by Business Segment (2014-2016)
  • 113 JOHNSON & JOHNSON: Net Revenue by Region (2014-2016)
  • 114 JOHNSON & JOHNSON: Net Revenue by Medical Devices Business Segment (2014-2016)
  • 115 JOHNSON & JOHNSON: SWOT Analysis
  • 116 MDxHealth, Inc.: Overall Financials (2014-2016)
  • 117 MDxHealth, Inc.: SWOT Analysis
  • 118 Menarini Silicon Biosystems, Inc.: Product Mapping
  • 119 Menarini Silicon Biosystems, Inc.: SWOT Analysis
  • 120 Myriad Genetics, Inc.: Product Mapping
  • 121 Myriad Genetics, Inc.: Overall Financials (2014-2016)
  • 122 Myriad Genetics, Inc.: Net Revenue by Business Segment (2014-2016)
  • 123 Myriad Genetics, Inc.: SWOT Analysis
  • 124 Natera, Inc.: Product Mapping
  • 125 Natera, Inc.: Overall Financials (2014-2016)
  • 126 Natera, Inc.: Net Revenue by Region (2014-2016)
  • 127 Natera, Inc.: SWOT Analysis
  • 128 NeoGenomics Laboratories, Inc.: Product Mapping
  • 129 NeoGenomics Laboratories, Inc.: Overall Financials (2014-2016)
  • 130 NeoGenomics Laboratories, Inc.: Net Revenue by Business Segment (2014-2016)
  • 131 NeoGenomics Laboratories, Inc.: SWOT Analysis
  • 132 QIAGEN: Product Mapping
  • 133 QIAGEN: Overall Financials (2014-2016)
  • 134 QIAGEN: Net Revenue by Region (2014-2016)
  • 135 Qiagen: Revenue by Business Segments (2014-2016)
  • 136 QIAGEN: SWOT Analysis
  • 137 RainDance Technologies, Inc.: Product Mapping
  • 138 RainDance Technologies, Inc.: Overall Financials (2014)
  • 139 RainDance Technologies: Net Revenue by Region (2014)
  • 140 RainDance Technologies, Inc.: SWOT Analysis
  • 141 Sysmex Corporation: Product Mapping
  • 142 Sysmex Corporation: Overall Financials (2014- 2016)
  • 143 Sysmex Corporation: Revenue by Business Segment (2014-2016)
  • 144 Sysmex Corporation: Revenue by Region(2014-2016)
  • 145 Sysmex Corporation: SWOT Analysis
  • 146 Thermo Fisher Scientific: Product Mapping
  • 147 Thermo Fisher Scientific: Overall Financials (2014-2016)
  • 148 Thermo Fisher Scientific: Net Revenue by Business Segment (2014-2016)
  • 149 Thermo Fisher Scientific: Net Revenue by Region (2014-2016)
  • 150 Thermo Fisher Scientific: SWOT Analysis
  • 151 TROVAGENE, INC.: Product Mapping
  • 152 TROVAGENE, INC.: Overall Financials (2014-2016)
  • 153 TROVAGENE, INC.: SWOT Analysis
Back to Top